https://www.prnewswire.com/news-releases/lumakraslumykras-sotorasib-demonstrates-superior-progression-free-survival-over-docetaxel-in-first-positive-phase-3-trial-of-a-kras-g12c-inhibitor-in-non-small-cell-lung-cancer-301621632.html
0
0
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER - PR Newswire
9/11/22 at 10:05pm
Organization
PRNewswire
50 words
0
Comments
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced detailed results from the global Phase 3 CodeBreaK 200 trial, which showed once-daily oral...
You are the first to view
Create an account or login to join the discussion